金斯瑞生物科技(01548.HK)上半年預虧1.53億美元-1.77億美元
格隆匯8月2日丨金斯瑞生物科技(01548.HK)公佈,根據對集團最新未經審核管理賬目以及現有可得的資料的初步評估,公司董事會向公司股東及公司潛在投資者提供公司截至2020年6月30日止6個月的財務表現的最新資料。
(1)除傳奇生物科技股份有限公司(“傳奇”)以外的集團業務(非細胞療法業務)淨利潤:預計非細胞療法業務的利潤約為1610萬美元至1880萬美元;
(2)對傳奇的投資(細胞療法業務):預計傳奇的持續運營將錄得約8900萬美元至1.03億美元的虧損(不計入包括髮行A類可轉換可贖回優先股的佣金、該等優先股的公允價值變動以及上市費用造成的一次性費用),其中包括研發費用約9650萬美元至1.118億美元;及
(3)因A類可轉換可贖回優先股公允價值變動導致的約8000萬美元的一次性非現金費用,這是由於在傳奇於納斯達克全球市場上市後自動轉換了傳奇的所有已發行的A類優先股(加上A類優先股應計但未支付的任何股息)為普通股。公允價值的變動導致股份溢價的增加,而這在本質上對傳奇及其附屬公司的淨資產沒有影響。
於2020年6月30日,傳奇有現金及現金等價物約5.624億美元及定期存款約7560萬美元。
總體而言,集團預期於截至2020年6月30日止6個月錄得虧損約1.531億美元至1.773億美元,而2019年同期則錄得虧損約3330萬美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.